Midostaurin is used for treating aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, mast cell leukemia, and newly diagnosed acute myeloid leukemia with FLT3 mutation-positive. It was first introduced by Novartis Pharmaceuticals Corp in its drug Rydapt on Apr 28, 2017. 4 different companies have introduced drugs containing Midostaurin.

Midostaurin Patents

Given below is the list of patents protecting Midostaurin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Rydapt	US7973031	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	Oct 09, 2028	Novartis
Rydapt	US8222244	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity	Oct 29, 2022 (Expired)	Novartis
Rydapt	US8575146	Pharmaceutical uses of staurosporine derivatives	Dec 02, 2030	Novartis

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Midostaurin's patents.

Latest Legal Activities on Midostaurin's Patents

Given below is the list recent legal activities going on the following patents of Midostaurin.

Event	Date	Patent/Publication
Critical Events for all Patents
Court Processing Terminated	03 Apr, 2024	US7973031
Maintenance Fee Reminder Mailed	04 Mar, 2024	US8222244
Payment of Maintenance Fee, 12th Year, Large Entity	21 Dec, 2022	US7973031
Patent Term Extension Certificate	27 Apr, 2022	US7973031
Withdrawal of Application for PTE	10 Mar, 2022	US8222244
Notice of Final Determination -Eligible	10 Mar, 2022	US7973031
Payment of Maintenance Fee, 8th Year, Large Entity	21 Apr, 2021	US8575146
37 CFR 1.750 Request for reconsideration	15 Apr, 2021	US7973031
Notice of Final Determination -Election Required	18 Mar, 2021	US7973031
Notice of Final Determination -Election Required	18 Mar, 2021	US8222244

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳